A case presenting with the clinical characteristics of tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) without TNFRSF1A mutations successfully treated with tocilizumab
-
- Hosoya Tadashi
- Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Japan
-
- Mizoguchi Fumitaka
- Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Japan
-
- Hasegawa Hisanori
- Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Japan
-
- Miura Keiko
- Division of Surgical Pathology, Tokyo Medical and Dental University Hospital, Japan
-
- Koike Ryuji
- Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Japan Clinical Research Center, Tokyo Medical and Dental University Hospital, Japan
-
- Kubota Tetsuo
- Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Japan Graduate School of Health Care Sciences, Tokyo Medical and Dental University (TMDU), Japan
-
- Miyasaka Nobuyuki
- Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Japan
-
- Kohsaka Hitoshi
- Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Japan
書誌事項
- タイトル別名
-
- A Case Presenting with the Clinical Characteristics of Tumor Necrosis Factor (TNF) Receptor-associated Periodic Syndrome (TRAPS) without <i>TNFRSF1A</i> Mutations Successfully Treated with Tocilizumab
この論文をさがす
抄録
A 30-year-old woman had suffered from recurrent and self-limiting fevers since childhood. Although she had no mutations in the exons or introns of the tumor necrosis factor (TNF) receptor superfamily member 1A gene, her clinical characteristics were consistent with those of TNF receptor-associated periodic syndrome (TRAPS). She did not respond to treatment with etanercept, although tocilizumab therapy was successful, subsequently ameliorating her symptoms and preventing further inflammatory attacks. Interleukin-6 blocking therapy should be considered as a new alternative treatment in patients with TRAPS who do not respond to etanercept.<br>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 54 (16), 2069-2072, 2015
一般社団法人 日本内科学会